HB6400: To amend title XVIII of the Social Security Act to extend eligibility for certain payment increases for biosimilar biological products under the Medicare program.
- 1Introduced (current step)
- 2Passed One Chamber
- 3Passed Both Chambers
- 4Became Law
Here is how to read this bill
Start with the summary
It says what the bill does in plain language. The official text is one tab over.
Check where it is
The status badge says how far it has gotten. The History tab lists every step.
Follow it
We will email you when it moves. You need a free account.
Tell someone who votes on it
Email or call the sponsor, or find your own representatives, from the actions panel.
Bill information
Summary
To amend title XVIII of the Social Security Act to extend eligibility for certain payment increases for biosimilar biological products under the Medicare program.
Plain-language summary
This bill would change how Medicare pays for biosimilar drugs—cheaper versions of expensive biologic medications created through biotechnology. Currently, Medicare provides temporary higher payment rates for biosimilars to encourage their use instead of pricier original drugs. The bill extends how long these higher payment rates last. The bill was just introduced in Congress and hasn't moved to yet.
AI-generated summary
What can I do?
It's early in the process — messages to the sponsor and your representatives carry the most weight right now.
Contact Your Representatives
Calling or emailing is the most direct way to weigh in — offices tally constituent contacts.
Find Your RepresentativesShare This Bill
Sharing helps others in your district get informed and involved.
HB6400: To amend title XVIII of the Social Security Act to extend eligibility for certa…